Abstract 665
Background
The purpose of this study is to estimate 5-year survival rates for patients with early onset breast cancer, with and without a BRCA1/2, CHEK2, NOD2 mutation or TP53 polymorphisms and to identify prognostic factors among mutation carriers in breast cancer patients.
Methods
In a study conducted in the years 2007-2016 in the Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology, Gliwice Branch (COI) were analyzed prognostic factors and survival in 622 breast cancer including 60 BRCA mutation carriers, 46 CHEK2 mutation carriers, 29 NOD2 mutation carriers and 87 patients with TP53 polymorphisms. Control group was selected from breast cancer patients without mutation and polymorphisms (n = 400).
Results
The five–year rate of OS was 75.9% for pts with BRCA mutation, 94.4% for CHEK2 mutation carriers, 96.6% for NOD2 mutation carriers and 100% for patients with TP53 polymorphisms. BRCA mutation carriers had insignificantly worse survival as compared to control group (p = 0.180). Patients with CHEK2 mutation had significantly better OS than control group (p = 0.032). Similarly NOD2 mutation carriers had also significantly better OS than control group (p = 0.043). Patients with TP53 polymorphisms carriers had higher OS in comparison to control group (p = 0.002). In subgroup of pts with N0 (Without lymph node metastases) BRCA mutation carriers was characterized by the worst OS (81.1%) among carriers of other mutations: CHEK2 (94.7%, P = 0.021), NOD2 (95.3%, p = 0.092) and TP53 polymorphisms (100%, p = 0.007) or control group (94.4%, p = 0.022). Similar tendency was observed according to N+ subgroup and subgroup with tumor size T1-T2. Higher tumor size (HR = 2.85), lymph node metastases (HR = 2.93) and HER2 overexpression (HR = 1.49) were significant factors for worse OS. Positive ER status was associated with a better OS (HR = 0.52, p = 0.001). Age <40 years (HR = 0.71, p = 0.255) was insignificantly favorable factor.
Conclusions
CHEK2, NOD2 mutation carriers and patients with TP53 polymorphisms had better 5-year survival in comparison to patients with BRCA mutation and control group. Higher tumor size (T) and lymph node metastases (N+) were negative prognostic factors independently from the presence of mutations and polymorphisms.
Clinical trial identification
Legal entity responsible for the study
Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract